Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GI Innovation
Listed Korean bioventures are increasingly opting for rights offerings in a high interest rate environment, while unlisted firms are turning more to smaller-scale VC financings.
GI Innovation chairman and CEO B G Rhee talks about his ambitions for the Korean bispecific protein firm’s leading allergy and immuno-oncology pipeline assets and what is behind his confidence.
While Chinese bioventures continue to surge ahead in immuno-oncology R&D, NeoImmuneTech says its long-acting human IL-7 in combination with pembrolizumab shows Phase IIa clinical efficacy in gastrointestinal tumors. Another Korean firm, GI Innovation, says its bispecific fusion protein/pembrolizumab combo shows synergistic effects in solid tumors at Phase I/II.
An analysis of the Korea Drug Development Fund’s selection of projects for R&D grants so far this year shows more applications and particular support for domestic cell and gene therapy projects, reflecting the strong interest in this area globally.
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.